June 10, 2024 11:16 AM EDT
R&D

Skye's stock sinks fol­low­ing eye dis­ease fail­ure as com­pa­ny shifts fo­cus to obe­si­ty

Katherine Lewin

News Reporter

Skye Bio­science is aban­don­ing its en­tire eye dis­ease pipeline fol­low­ing a Phase 2a tri­al fail­ure, and it’s piv­ot­ing to one of the hottest cat­e­gories in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Jim Wilson's Gem­ma­Bio rais­es $34M to com­mer­cial­ize gene ther­a­pies for rare dis­eases

A service from the Financial Times